» Authors » Johan Ulander

Johan Ulander

Explore the profile of Johan Ulander including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 386
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Williams G, Ferenczy G, Ulander J, Keseru G
Drug Discov Today . 2016 Dec; 22(4):681-689. PMID: 27916639
Small is beautiful - reducing the size and complexity of chemical starting points for drug design allows better sampling of chemical space, reveals the most energetically important interactions within protein-binding...
12.
Kramer C, Dahl G, Tyrchan C, Ulander J
Drug Discov Today . 2016 Apr; 21(8):1213-21. PMID: 27063506
Analysis of data from various compounds measured in diverse biological assays is a central part of drug discovery research projects. However, no systematic overview of the variability in biological assays...
13.
Grebner C, Iegre J, Ulander J, Edman K, Hogner A, Tyrchan C
J Chem Inf Model . 2016 Mar; 56(4):774-87. PMID: 26974351
Computer-aided drug design plays an important role in medicinal chemistry to obtain insights into molecular mechanisms and to prioritize design strategies. Although significant improvement has been made in structure based...
14.
Geschwindner S, Ulander J, Johansson P
J Med Chem . 2015 Apr; 58(16):6321-35. PMID: 25915439
The use of ligand binding thermodynamics has been proposed as a potential success factor to accelerate drug discovery. However, despite the intuitive appeal of optimizing binding enthalpy, a number of...
15.
Lemurell M, Ulander J, Winiwarter S, Dahlen A, Davidsson O, Emtenas H, et al.
J Med Chem . 2014 Dec; 58(2):897-911. PMID: 25478788
A drug discovery program in search of novel 5-lipoxygenase activating protein (FLAP) inhibitors focused on driving a reduction in lipophilicity with maintained or increased ligand lipophilic efficiency (LLE) compared to...
16.
Fagerberg J, Karlsson E, Ulander J, Hanisch G, Bergstrom C
Pharm Res . 2014 Sep; 32(2):578-89. PMID: 25186438
Purpose: To develop predictive models of apparent solubility (Sapp) of lipophilic drugs in fasted state simulated intestinal fluid (FaSSIF) and aspirated human intestinal fluid (HIF). Methods: Measured Sapp values in...
17.
Gustafsson D, Nielsen S, McPheat J, Wagberg F, Kaspersson K, Rohman M, et al.
Thromb Res . 2013 Jul; 132(2):248-55. PMID: 23830061
Introduction: Oral treatment is lacking for haemophilia, the rare bleeding disorders, and some severe forms of von Willebrand's disease. We have serendipitously identified a small molecule procoagulant compound (AZ10047130). This...
18.
Plowright A, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, et al.
J Med Chem . 2012 Dec; 56(1):220-40. PMID: 23227781
Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are...
19.
Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, van der Graaf P
Curr Top Med Chem . 2011 Feb; 11(4):404-18. PMID: 21320067
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system proper¬ties, enabling prediction of the magnitude and time course of drug responses under physiological...
20.
Wan H, Bold P, Larsson L, Ulander J, Peters S, Lofberg B, et al.
Curr Drug Metab . 2010 Jul; 11(7):583-94. PMID: 20629632
The in vitro metabolic stability assays are indispensable for screening the metabolic liability of new chemical entities (NCEs) in drug discovery. Intrinsic clearance (CL(int)) values from liver microsomes and/or hepatocytes...